HEALTHCARE PROFESSIONAL RESOURCES

  • Metastatic
    Breast Cancer

    The ABRAXANE Journey: A History of Looking Ahead

    Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.

    ABRAXANE Reconstitution Video

    This video will guide you through the appropriate process of reconstituting ABRAXANE.

    ABRAXANE Full Prescribing Information

    Download the Prescribing Information for ABRAXANE.

    ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

    CLOSE THE TAB
  • Advanced Non–Small
    Cell Lung Cancer

    Advanced Squamous NSCLC and the Assessment of Tumor Response Video

    Explore the characteristics of advanced squamous NSCLC and its clinical manifestations.

    The ABRAXANE Journey: A History of Looking Ahead

    Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.

    ABRAXANE Reconstitution Video

    This video will guide you through the appropriate process of reconstituting ABRAXANE.

    Understanding Squamous NSCLC Through Virtual Reality

    The NanoExplorer is an immersive, 360-degree virtual reality experience that highlights the type of patients with aNSCLC who are appropriate for treatment with ABRAXANE + carboplatin by taking the doctor on a journey inside a patient’s body to explore tumor histology, PD-L1 expression level, and actionable mutation status. Set up a presentation in your office today.

    ABRAXANE Full Prescribing Information

    Download the Prescribing Information for ABRAXANE.

    ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

    CLOSE THE TAB
  • Metastatic
    Pancreatic Cancer

    The ABRAXANE Journey: A History of Looking Ahead

    Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.

    MPACT Study Videos

    Dr. George Kim reviews the MPACT study–the largest multinational Phase III study in metastatic pancreatic cancer (MPAC) using ABRAXANE + gemcitabine in the first-line setting.

    MPACT Study Design
    Dr. Kim presents the study design and results in the MPACT study.

    MPACT Efficacy
    Dr. Kim presents the efficacy results for ABRAXANE in the MPACT study (including OS, ORR, and PFS).

    MPACT Safety
    Dr. Kim presents the safety results for ABRAXANE in the MPACT study.

    MPACT Dosing
    Dr. Kim presents dosing and schedule recommendations for ABRAXANE in the MPACT study.

    ABRAXANE Reconstitution Video

    This video will guide you through the appropriate process of reconstituting ABRAXANE.

    Knowledge Is Power in Treating MPAC

    Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring MPAC patients receive the most appropriate treatments.

    NEJM Clinical Reprint

    Results from the Phase III Study: ABRAXANE plus gemcitabine for MPAC.

    MPAC Dosing Card

    Dosing Instructions for ABRAXANE MPAC indication including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.

    MPAC NCCN Flashcard

    Learn about ABRAXANE + gemcitabine’s NCCN Category 1 recommendation in metastatic pancreatic cancer patients with good performance status (ECOG 0-1) and as a reasonable option for patients with KPS 70.

    ABRAXANE Full Prescribing Information

    Download the Prescribing Information for ABRAXANE.

    ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

    Knowledge Is Power in Treating MPAC

    Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring MPAC patients receive the most appropriate treatments.

    NEJM Clinical Reprint

    Results from the Phase III Study: ABRAXANE plus gemcitabine for MPAC.

    MPAC Dosing Card

    Dosing Instructions for ABRAXANE MPAC indication including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.

    MPAC NCCN Flashcard

    Learn about ABRAXANE + gemcitabine’s NCCN Category 1 recommendation in metastatic pancreatic cancer patients with good performance status (ECOG 0-1) and as a reasonable option for patients with KPS 70.

    ABRAXANE Full Prescribing Information

    Download the Prescribing Information for ABRAXANE.

    ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

    CLOSE THE TAB
  • Metastatic Breast Cancer

    The ABRAXANE Journey: A History of Looking Ahead

    Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.

    ABRAXANE Reconstitution Video

    This video will guide you through the appropriate process of reconstituting ABRAXANE.

    ABRAXANE Full Prescribing Information

    Download the Prescribing Information for ABRAXANE.

    ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

    CLOSE THE TAB
  • Advanced Non–Small Cell Lung Cancer

    Advanced Squamous NSCLC and the Assessment of Tumor Response Video

    Explore the characteristics of advanced squamous NSCLC and its clinical manifestations.

    The ABRAXANE Journey: A History of Looking Ahead

    Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.

    ABRAXANE Reconstitution Video

    This video will guide you through the appropriate process of reconstituting ABRAXANE.

    Understanding Squamous NSCLC Through Virtual Reality

    The NanoExplorer is an immersive, 360-degree virtual reality experience that highlights the type of patients with aNSCLC who are appropriate for treatment with ABRAXANE + carboplatin by taking the doctor on a journey inside a patient’s body to explore tumor histology, PD-L1 expression level, and actionable mutation status. Set up a presentation in your office today.

    ABRAXANE Full Prescribing Information

    Download the Prescribing Information for ABRAXANE.

    ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

    CLOSE THE TAB
  • Metastatic Pancreatic Cancer

    The ABRAXANE Journey: A History of Looking Ahead

    Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.

    MPACT Study Videos

    Dr. George Kim reviews the MPACT study–the largest multinational Phase III study in metastatic pancreatic cancer (MPAC) using ABRAXANE + gemcitabine in the first-line setting.

    MPACT Study Design
    Dr. Kim presents the study design and results in the MPACT study.

    MPACT Efficacy
    Dr. Kim presents the efficacy results for ABRAXANE in the MPACT study (including OS, ORR, and PFS).

    MPACT Safety
    Dr. Kim presents the safety results for ABRAXANE in the MPACT study.

    MPACT Dosing
    Dr. Kim presents dosing and schedule recommendations for ABRAXANE in the MPACT study.

    ABRAXANE Reconstitution Video

    This video will guide you through the appropriate process of reconstituting ABRAXANE.

    Knowledge Is Power in Treating MPAC

    Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring MPAC patients receive the most appropriate treatments.

    NEJM Clinical Reprint

    Results from the Phase III Study: ABRAXANE plus gemcitabine for MPAC.

    MPAC Dosing Card

    Dosing Instructions for ABRAXANE MPAC indication including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.

    MPAC NCCN Flashcard

    Learn about ABRAXANE + gemcitabine’s NCCN Category 1 recommendation in metastatic pancreatic cancer patients with good performance status (ECOG 0-1) and as a reasonable option for patients with KPS 70.

    ABRAXANE Full Prescribing Information

    Download the Prescribing Information for ABRAXANE.

    ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

    Knowledge Is Power in Treating MPAC

    Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring MPAC patients receive the most appropriate treatments.

    NEJM Clinical Reprint

    Results from the Phase III Study: ABRAXANE plus gemcitabine for MPAC.

    MPAC Dosing Card

    Dosing Instructions for ABRAXANE MPAC indication including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.

    MPAC NCCN Flashcard

    Learn about ABRAXANE + gemcitabine’s NCCN Category 1 recommendation in metastatic pancreatic cancer patients with good performance status (ECOG 0-1) and as a reasonable option for patients with KPS 70.

    ABRAXANE Full Prescribing Information

    Download the Prescribing Information for ABRAXANE.

    ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL